# EDGAR Filing Document

**Accession Number:** 0001505512
**File Stem:** 0000950170-25-091003
**Filing Date:** 2025-6
**Character Count:** 12119
**Document Hash:** cc60cacc4b23efbee26d8e9a2a380c29
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-091003.hdr.sgml**: 20250627

**ACCESSION NUMBER**: 0000950170-25-091003

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250625

**FILED AS OF DATE**: 20250627

**DATE AS OF CHANGE**: 20250627

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Huang Alice Shih-hou
- **CENTRAL INDEX KEY:** 0001842618

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35670
- **FILM NUMBER:** 251087473

**MAIL ADDRESS:**
- **STREET 1:** C/O REGULUS THERAPEUTICS INC.
- **STREET 2:** 4224 CAMPUS POINT CT., SUITE 210
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Regulus Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001505512
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 264738379
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 4224 CAMPUS POINT COURT
- **STREET 2:** SUITE 210
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 858-202-6300

**MAIL ADDRESS:**
- **STREET 1:** 4224 CAMPUS POINT COURT
- **STREET 2:** SUITE 210
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[x] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Huang Alice Shih-hou<br><sub>(Last) (First) (Middle)</sub><br>C/O REGULUS THERAPEUTICS INC.<br>4224 CAMPUS POINT CT., #210<br><sub>(Street)</sub><br>SAN DIEGO, CA 92121<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-06-25 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Regulus Therapeutics Inc. [ RGLS ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-06-25 |  | U<sup>(1)(2)</sup> |  | 5208 | D | <sup>(3)</sup> | 57292 | D |  |
| Common Stock | 2025-06-25 |  | D<sup>(1)(2)</sup> |  | 57292 | D | <sup>(4)</sup> | 0 | D |  |
| Common Stock | 2025-06-25 |  | U<sup>(1)(2)</sup> |  | 27377 | D | <sup>(3)</sup> | 57292 | I | By Spouse |
| Common Stock | 2025-06-25 |  | D<sup>(1)(2)</sup> |  | 57292 | D | <sup>(4)</sup> | 0 | I | By Spouse |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option | $9.90 | 2025-06-25 |  | D<sup>(1)(2)</sup> |  |  | 4000 | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 4000 | <sup>(6)</sup> | 0 | D |  |
| Stock Option | $2.70 | 2025-06-25 |  | D<sup>(1)(2)</sup> |  |  | 9000 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 9000 | <sup>(5)</sup> | 0 | D |  |
| Stock Option | $1.45 | 2025-06-25 |  | D<sup>(1)(2)</sup> |  |  | 30000 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 30000 | <sup>(5)</sup> | 0 | D |  |
| Stock Option | $1.36 | 2025-06-25 |  | D<sup>(1)(2)</sup> |  |  | 15000 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 15000 | <sup>(5)</sup> | 0 | D |  |
| Stock Option | $2.01 | 2025-06-25 |  | D<sup>(1)(2)</sup> |  |  | 30000 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 30000 | <sup>(5)</sup> | 0 | D |  |
| Stock Option | $2.01 | 2025-06-25 |  | D<sup>(1)(2)</sup> |  |  | 60000 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 60000 | <sup>(5)</sup> | 0 | D |  |
| Stock Option | $6.40 | 2025-06-25 |  | D<sup>(1)(2)</sup> |  |  | 4650 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 4650 | <sup>(5)</sup> | 0 | I | By Spouse |
| Stock Option | $8.80 | 2025-06-25 |  | D<sup>(1)(2)</sup> |  |  | 2325 | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 2325 | <sup>(6)</sup> | 0 | I | By Spouse |
| Stock Option | $9.90 | 2025-06-25 |  | D<sup>(1)(2)</sup> |  |  | 4000 | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 4000 | <sup>(6)</sup> | 0 | I | By Spouse |
| Stock Option | $2.70 | 2025-06-25 |  | D<sup>(1)(2)</sup> |  |  | 9000 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 9000 | <sup>(5)</sup> | 0 | I | By Spouse |
| Stock Option | $1.45 | 2025-06-25 |  | D<sup>(1)(2)</sup> |  |  | 30000 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 30000 | <sup>(5)</sup> | 0 | I | By Spouse |
| Stock Option | $1.36 | 2025-06-25 |  | D<sup>(1)(2)</sup> |  |  | 15000 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 15000 | <sup>(5)</sup> | 0 | I | By Spouse |
| Stock Option | $2.01 | 2025-06-25 |  | D<sup>(1)(2)</sup> |  |  | 30000 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 30000 | <sup>(5)</sup> | 0 | I | By Spouse |
| Stock Option | $2.01 | 2025-06-25 |  | D<sup>(1)(2)</sup> |  |  | 60000 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 60000 | <sup>(5)</sup> | 0 | I | By Spouse |

---

### Footnotes:

(1) This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share.

(2) Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.

(3) Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for the Offer Price.

(4) Pursuant to terms of the Merger Agreement,  each restricted stock unit that was subject to vesting or forfeiture conditions that was outstanding immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive  (i) an amount in cash (without interest and subject to applicable withholding) equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such restricted stock unit immediately prior to the Effective Time by (B) the Closing Amount, plus (ii) one CVR with respect to each Share subject to such restricted stock unit immediately prior to the Effective Time.

(5) Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an "In-the-Money Option") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time.

(6) Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an "Out-of-the-Money Option") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option).

**Signature:** /s/ Christopher Aker, Attorney-in-Fact  
**Date:** 2025-06-27

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**